Upcoming Events
Log In
Pricing
Free Trial

Wk 1, Case 2 - Review

HIDE
PrevNext

0:04

Okay, so the next

0:05

Case is, it was the Sotal monitory nodule case.

0:10

It's one, it's one of the first indication that

0:12

PET was approved for it.

0:15

The sotal mono nodule. Again, the brain was negative.

0:18

Here I'm just showing you have to get your eye used

0:20

to how to look at the brain.

0:22

You are looking quickly through the brain, brain mass,

0:25

symmetric, no high focal, um, hypermetabolic

0:28

or hypermetabolic activity.

0:30

And then you increase the intensity

0:32

and go through it, look forward the scalp

0:34

and the skull, um, go down.

0:38

There was nothing really attracting our attention

0:43

here till you see this

0:47

Here.

0:48

And actually this patient is referred to us for, um,

0:51

This nodule.

0:53

So, um, you are, um, you have to,

0:57

you already know this nodule.

0:58

So, um, usually actually,

1:02

and I'm sure you already saw by now, uh,

1:06

saw my report, right?

1:09

And you saw how I, I usually start with the questionable,

1:13

um, nodule.

1:15

This is how I start. Because usually the patient is sent

1:18

to you with, um, a nodule workup.

1:23

Uh, this is a very valid, legitimate indication.

1:27

Look at this, uh, p monitoring nodule.

1:30

And usually you have, um, uh, the agnostic CT chest

1:33

with full inspiration, thin, thinner slices, different,

1:37

um, kernel.

1:39

So you can see, have a better look at the nodule

1:43

than our tidal volume.

1:45

And we have to do tidal volume ct.

1:47

It's not that we don't have the capability

1:49

of doing a diagnostic ct.

1:50

We can do a diagnostic ct,

1:52

but remember that you, you

1:53

to acquire the pet table position, you need three, four, uh,

1:58

minutes for each table position.

2:00

Um, and to register this pet to this ct, you cannot have,

2:04

uh, this the, for example, if the initial time with the pet

2:10

time, they, we used to do a full inspiration ct

2:13

and then you do this, the pet

2:14

and you have to do, have the pet on the tidal volume

2:16

because you can't ask the patient to keep his, uh, uh,

2:21

breath for three minutes, right?

2:24

But then try to register a title volume PET

2:27

to a full inspiration, um, city

2:31

total misregistration.

2:33

So the only way to do this

2:35

and have a decent registration between the PET

2:37

and a CT is to have both of them done

2:41

with a patient breathing quietly.

2:43

This is why we cannot

2:44

Do a full inspiration CT in our PET ct.

2:48

Um, but

2:49

otherwise we have the capability of of getting,

2:51

doing a diagnostic CT

2:52

In our scanners, Right?

2:55

So bottom line is you have the diagnostic CT already

2:58

Available to you to review while looking at your pet ct.

3:01

And you look at this, but you are doing this to look

3:04

for the metabolic activity.

3:06

Now this usually this, um, nodule is when

3:11

by the time they send this to you, a lot

3:13

of time it's like eight millimeter, nine millimeter nodule.

3:16

A lot of times not even a centimeter, which is usually

3:20

below our, um, pet resolution.

3:22

The pet resolution is usually a centimeter.

3:26

So you have, um, a nodule that is below your PET resolution

3:30

or within, like just add the pet resolution border,

3:33

which is a centimeter.

3:34

And then you're looking for activity.

3:36

And you look at this activity, it's

3:38

above the liver parenchyma, right?

3:41

So it's not only above the blood pools,

3:42

above the liver parenchyma.

3:43

So this is sus suspicious enough, right?

3:46

So you have the imaging feature that is suspicious

3:48

and you have the, there is there,

3:50

it's exhibiting metabolic uptake.

3:54

So you are gonna say it is suspicious for malignancy

3:58

and you will ask for tissue sampling for sure.

4:01

But this is not only your job here, your job is not done.

4:05

You still have to look for lymph nodes.

4:08

Do you think there is lymph nodes?

4:09

You look at the ipsilateral hilar region, right?

4:13

You look at the epi medias no lesion.

4:16

I'm looking at the peton. There is nothing

4:17

that is suspicious to me.

4:20

Right? And then you look retro choal,

4:26

of course you'll look for other nodules in the

4:28

lung very carefully.

4:30

Make sure there's nothing else.

4:31

You are either are incidental findings, of course scarring.

4:34

If emus changes all this you'll mention.

4:37

But, and we do look at the ct.

4:40

There's nothing like CT is for the,

4:42

for attenuation correction

4:43

and low resolution CT for attenuation correction.

4:46

This is, I'm sorry, but this is nonsense.

4:47

You have a decent ct, not bad ct. Yes.

4:50

It's not a, it's not like the same quality

4:52

as the full inspiration diagnostic city,

4:54

but you can draw a lot of information outta the city.

4:57

So you have to read it.

4:58

You cannot just like, dismiss it totally

5:00

and say, okay, this is nothing.

5:01

I'm just have this nodule

5:03

that is hot and you're just like done.

5:04

And your, your report is done.

5:05

You have to do a good job and get as much information

5:08

as you can from this, right?

5:11

And so nothing, no nodules, no other nodules, no,

5:15

definitely not, no hypermetabolic nodules, no other nodules,

5:19

no lymph nodes, no metastatic lymph nodes, right?

5:22

Then you will go and look for the other sides of meds.

5:26

Adrenal the lung, you know that the,

5:31

um, adrenals, um,

5:35

do you guys still hear me?

5:40

Yes, we can hear you. Um,

5:41

'cause I, it's gave me a message that something like, um,

5:44

the microphone was changed or something.

5:47

So, and then the adrenals, for example,

5:49

is very important for the lung.

5:50

For the lung cancer. You look this, this fatty liver.

5:52

There is gold stones.

5:54

You will mention all these incidentals in your report,

5:56

but you're looking at the pet.

5:58

There is no other metastatic disease.

6:00

You will look in sagittal coronal.

6:03

There is no bone mets, no liver mets, no nothing else.

6:06

So the conclusion is that this nodule,

6:08

this small nodule exhibits mild, um, metabolic active, mild,

6:13

moderate metabolic activity, suspicious for malignancy, um,

6:18

tissue sampling is recommended.

6:20

And then you will say you are not done.

6:22

There's no suspicious, um, hy mein lymphadenopathy.

6:25

There is no evidence of meta hypermetabolic

6:28

or metabolically active

6:29

metastatic distant metastatic disease.

6:31

So you had the t you,

6:33

you said that the nodule is suspicious.

6:35

You said that there is no the n there's no no,

6:37

there's no suspicious lymph node.

6:39

You hit the m there is no

6:41

suspicious systemic metastatic disease.

6:42

So here you would not, not only told them

6:44

that this nodule is suspicious,

6:46

but you told them also

6:47

that the N is is most probably zero now,

6:50

and the M is most probably zero now.

6:52

So this is, you also stage the patient for them

6:56

once they get the pathology.

6:58

So then you concluded the case.

7:00

So you have significantly in this case.

Report

Please note: Items with dashed lines (--) are information withheld as it is not relevant for you to arrive at the correct findings and impression for the report and/or it was withheld for privacy information. The items were left in to show you the typical information documented in a PET report.

Clinical Indication:
---year-old ----- with history of HIV. Most recent CT chest short interval increase in size of a right lower lobe pulmonary nodule. PET/CT is performed for metabolic characterization of this enlarging pulmonary nodule.

Technique:
Preparation: Last oral intake (except water) on --at --.
Diabetic: --.
Blood glucose at time of FDG administration: --- mg/dL.
Radiopharmaceutical: -- mCi of F-18 FDG administered IV at -- at --.
Incubation interval: -- minutes.
Oral contrast: --.
Positioning: Arms raised
PET/CT scanner: ---.
PET/CT acquisition: Vertex-to-midthigh.
PET reconstruction method: ---
Standardized uptake value (SUV): Corrected for body weight only.
CT: Low-dose, non-breath-hold, without intravenous contrast.
TOTAL DLP (Dose Length Product): -- mGy cm.

Comparison/Correlation:
No relevant prior imaging for comparison

Findings:
Technical quality:--------.
Measurements: Unless otherwise specified, all SUVs refer to maximum value in the target and all CT linear measurements are performed on axial images.
Reference: mean SUV liver: ----

HEAD AND NECK:
No suspicious hypermetabolic foci within the head and neck.
No suspicious hypermetabolic or pathologically enlarged cervical lymph nodes.
Mildly FDG avid sub-centimeter left intra-parotid nodule maximum SUV 2.5, likely primary parotid neoplasm such as pleomorphic adenoma or Warthin's tumor. Attention on follow-up scans recommended.
The thyroid is unremarkable.


CHEST:
The questionable pulmonary nodule within the right lower lobe azygo-esophageal recess exhibits mild to moderate FDG uptake, maximum SUV 3.5.
No suspicious hypermetabolic or pathologically enlarged mediastinal, hilar or axillary lymph nodes. Calcified mediastinal and right hilar lymph nodes.
Faint FDG avidity associated with a linear reticular slightly hyperdense opacity within the right upper lobe, maximum SUV 0.6, likely inflammatory.
Severe upper lobe predominant centrilobular emphysema.
Mild calcified atherosclerotic plaque of the thoracic aorta.
Multivessel coronary artery calcifications.


ABDOMEN AND PELVIS:
No suspicious hypermetabolic foci within the abdomen and pelvis.
There are no hypermetabolic or pathologically enlarged mesenteric, retroperitoneal, pelvic or inguinal lymph nodes.
Unremarkable liver, spleen, pancreas, adrenal glands, and kidneys.
Cholelithiasis.
Physiologic FDG avidity throughout loops of small and large bowels. Colonic diverticulosis.
There is no ascites.
Moderate aortoiliac atherosclerotic calcifications. Abdominal aortic aneurysm with chronic dissection.
Prostatomegaly, without associated focal hypermetabolism.


MUSCULOSKELETAL:
No suspicious hypermetabolic osseous or soft tissue lesions.
Mild FDG avidity associated with hypertrophic facets of the lower lumbar spine, maximum SUV 2.7, likely facet joint arthropathy.
Grade 1 anterolisthesis of C3 on C4. Multilevel degenerative changes.
Stable appearance of non-FDG avid mild superior endplate deformity of T12 with less than 50% loss of vertebral height.
There are no suspicious lytic or sclerotic osseous lesions.

Impression:
1. The questionable nodule within the right lower lobe azygo-esophageal recess exhibits moderate FDG uptake and highly suspicious for a primary lung malignancy. Tissue sampling recommended.
2. No convincing evidence of metabolically active regional or distant metastatic disease.

Case Discussion

Faculty

Riham El Khouli, MD

Associate Professor of Radiology, Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics

University of Kentucky

Michael F. Shriver, MD

Director of Nuclear Medicine

Proscan-NCH Imaging

Tags

PET/CT FDG

PET

Nuclear Medicine

Lungs

CT